(Q79409162)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

title

Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Francisco J Esteva

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

8

Aman U Buzdar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

Chafika Mazouni

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Angeline Hall

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Kristine Broglio

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Herbert Fritsche

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Gabriel N Hortobagyi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Lajos Pusztai

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Massimo Cristofanilli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

publication date

1 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

volume

109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

page(s)

496-501

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

22 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

The basic biology of HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Monitoring therapy by serum HER-2/neu

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Tumor markers in breast cancer- European Group on Tumor Markers recommendations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

ElevatederbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22418

7 January 2021

Identifiers

DOI

10.1002/CNCR.22418

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17149760%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference